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Science has progressed fast in providing answers to probiotic health benefits to the consumers. This 
symposium also proves that progress is fast. However, several challenges still need to be solved and more 
effective strains and strain combinations discovered. This will pave the way from good probiotics to 
specific products for clearly identified target populations.  The intestinal microbiota and its interaction(s) 
with probiotics challenges researchers to turn to the next new page to discover new approaches and 
treatment modalities that utilize probiotics as means of providing good nutrition with clear health benefits 
to all consumers. 
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The healthy human microbiota is a metabolic organ which 
provides a defence system against harmful environmental 
exposures. This active complex community consists of 
more cells than can be found in our body and contains 
about 1.5 kg of viable microbes. Deviations in composition 
can be related to multiple disease states within the intestine 
but also beyond it. Similarly, components of the human 
intestinal microbiota or organisms entering the intestine 
may have both harmful and beneficial effects on human 
health.  
     A probiotic has been defined by the ILSI Europe 
(International Life Sciences Insitute Europe) working 
group as “a viable microbial food supplement which bene-
ficially influences the health of the host”.1  This definition 
has been refined by the FAO/WHO expert group in 20022 
to include the required dose.  Both definitions require 
scientifically demonstrated efficacy and safety.  Selection 
criteria for future probiotics have been developed towards 
target-specific criteria, but they also include adhesion to 
intestinal mucosa, and acid and bile tolerance as the key 
selection factors.  The benefits of probiotics have been ana-
lysed in meta-analysis studies published elsewhere.1 
     In order to demonstrate health effects and benefits, 
research has been conducted on mechanisms of action and 
clinical intervention studies with human subjects belonging 
to the target groups. As an example, a meta-analysis of 
effects in acute diarrhoea has been published recently.3  The 
issues covered in this symposium include studies of well-
established probiotic strains and strain combinations which 
have been demonstrated to have additive and synergistic in 
vitro properties, discussion of the issue of safety of pro-
biotics for use in foods, the best methods for  delivering 
probiotics to the gut, and clinical studies on use of 
probiotics in inflammatory bowel disease.  The future tar-
get is to increase the genomic information on both pro-
biotics and microbiota to improve the understanding of 
specific intestinal diseases.  Thereafter, the goal is to apply 
the knowledge of microbiota composition and aberrancies 
on selecting the right probiotic combinations for defined 
target populations to maintain healthy gut microbiota and 
to improve human health and well-being.  
     Probiotic science has developed rapidly during the last 
decade.  In this issue we again see a variety of scientific 
studies, both intervention and other studies, on probiotics. 
Data on potential health effects is accumulating and faci-
litates the understanding of interactions of specific pro-
biotics and intestinal microbiota.  There are still several 
unanswered questions including the following:  
1. Could smaller probiotic doses be administered to 
infants and children with a less complex microbiota 
than for adults with a stable, diverse and more com-
plex microbiota?   
2. Are larger doses, longer treatment times and perhaps 
specific probiotic combinations required for elderly 
subjects or subjects with specific intestinal micro-
biota deviations?  
3. How important is the viability of the probiotics for 
health effects? These are among the key issues for 
future research. 
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Genome and function studies of current probiotics will 
increase our understanding on the biological mechanisms 
in cases where clinical efficacy has been demonstrated. 
Clinical data on the beneficial role of specific probiotic 
strains, and combinations has increased significantly and 
is accumulating at a rapid pace. Combining together the 
genomic data with host-microbe interaction studies will 
enable us to develop future probiotics using metabolomic 
approaches.  This will facilitate development of probiotic 
preparations which are more specific for both maintaining 
healthy intestinal microbiota and designed for particular 
target populations to promote health and to reduce the risk 
of specific diseases.  Such information will redefine the 
way we select, characterize and assess future probiotics 
and especially probiotic combinations in a scientifically 
valid manner.4 
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透過腸道菌群調整及益生菌來影響健康 
NSA益生菌研討會引言，Nov/Dec 2006 
 
科學已經快速進步提供關於益生菌健康益處的答案給消費者，這個研討會同樣證
明那個快速進步。然而，有好幾個挑戰仍待解決，而更多的有效菌株及菌株結合
體也有待發現。這個將為從好的益生菌產品到清楚定義的目標族群鋪路。腸道菌
群及其與益生菌的交互作用挑戰研究者，轉向去發現利用益生菌以提供好的營養
及清楚的健康益處給所有的消費者的新方法及治療形式的新頁。 
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